Prognosis

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

Retrieved on: 
Thursday, June 1, 2023
CRPC, Neoplasm, Survival, NUT, CRADA, Quality of life, Lung cancer, Head, Prognosis, Carcinoma, NUT carcinoma, Neck, Bangladesh Technical Education Board, BET, Development, National Cancer Institute, Cancer, Cooperative research and development agreement, Patient, Colorectal cancer, Drug combination, Zenith, Diagnosis, CTEP, Ovarian cancer, Breast cancer, NCI, NIH, Disease, Pharmaceutical industry

Zenith's BET inhibitor ZEN-3694 providing significant clinical benefit in patients with aggressive cancer type

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC).
  • Zenith Epigenetics has provided ZEN-3694 to two NC patients for compassionate use and both experienced significant clinical benefit and durable reduction of their tumors.
  • "We are very pleased that NUT carcinoma patients receiving ZEN-3694 for compassionate use have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.
  • We continue to advance these programs with our partners and are committed to bring this important therapy to these patients."

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

Retrieved on: 
Thursday, June 1, 2023
CD38, Therapy, Doctor of Philosophy, Symantec Endpoint Protection, Overalls, Cancer, Prognosis, Patient, ETB (company), Multiple myeloma, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, Pharmaceutical industry

The FDA placed the Phase I study for MT-0169 on a partial clinical hold in April 2023, based on previously disclosed asymptomatic and fully reversible cardiac adverse events (“AEs”) noted in two patients dosed at 50 mcg/kg which prompted the dose reduction to 5 mcg/kg last year.

Key Points: 
  • The FDA placed the Phase I study for MT-0169 on a partial clinical hold in April 2023, based on previously disclosed asymptomatic and fully reversible cardiac adverse events (“AEs”) noted in two patients dosed at 50 mcg/kg which prompted the dose reduction to 5 mcg/kg last year.
  • “We are pleased that the FDA has removed the partial clinical hold,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of MTEM.
  • “MT-0169 represents a novel approach to myeloma that is demonstrating good safety with early signs of potential clinical benefit, particularly in the extramedullary setting, where we have seen a stringent Complete Response in a patient who remains on study for 10 months.”
    MTEM will be focusing development of MT-0169 on extramedullary myeloma, a form of myeloma that is less responsive to current therapies and carries a worse overall prognosis.
  • Up to 20% of patients with relapsed/refractory multiple myeloma have extramedullary disease.

Pangaea Data Awarded Strategic Partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC) to Characterize Patients Across Hard-to-diagnose Mental Health Conditions

Retrieved on: 
Thursday, June 1, 2023
Technology, Mental Health, Clinical Trials, Health Technology, Professional Services, Health, Data Analytics, Data Management, Artificial Intelligence, National Institute for Health and Care Research, Metadata, Partnership, Psychosis, University, DSM-IV codes, Mental health, Intelligence, Innovation, Prognosis, NLP, Mersey Care NHS Foundation Trust, Patient, Mental, Mental health inequality, Artificial intelligence, NHS, UK, Nursing, Pharmaceutical industry, Pangaea, Research

M-RIC will be applying Pangaea’s product to characterize patients across hard-to-diagnose mental health conditions and discover new clinically actionable intelligence, which will help to find more undiagnosed, misdiagnosed and miscoded patients.

Key Points: 
  • M-RIC will be applying Pangaea’s product to characterize patients across hard-to-diagnose mental health conditions and discover new clinically actionable intelligence, which will help to find more undiagnosed, misdiagnosed and miscoded patients.
  • The discovery of new, clinically actionable signatures will improve clinicians’ knowledge of their patients’ journeys and enable them to select more appropriate clinical care pathways.
  • Clinicians will also gain insights into new areas of research and development, which in turn opens additional opportunities to collaborate with external teams.
  • Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We are excited to partner with Mersey Care NHS Foundation Trusts and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC).

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

Retrieved on: 
Thursday, June 1, 2023
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Other Science, Brainstem, L1, Attack, Glial fibrillary acidic protein, Serum, Disability, Spinal cord, RCP, Heinrich Heine University Düsseldorf, Philip Niarchos, Expanded Disability Status Scale, Prognosis, NMOSD, Brain, Medicine, Biomarker, Department of Neurology, Xuanwu hospital, Disease management, EDSS, Medical school, Journal, Journal of Neurology, Neurosurgery, and Psychiatry, Patient, Risk, Randomized controlled trial, Psychiatry, Optic nerve, Neurosurgery, Disease, Medical imaging

NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.

Key Points: 
  • NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.
  • Disease management goals are focused on prevention of attacks, as well as understanding and tracking biomarkers that could signal these attacks.
  • The strong link suggests that higher sNfL levels may be associated with more severe attacks and increased risk of residual disability.
  • Compared with placebo, UPLIZNA was shown to hinder biomarker elevation during attacks while reducing biomarker levels over time in the absence of attacks.

Burning Rock Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 30, 2023
LSE, Advertising, AACR, Travel, Water Drops on Burning Rocks, Methylation, Marketing, Cholangiocarcinoma, NGS, COVID-19, Lung cancer, Prognosis, Research, NSCLC, ID, PPV, MRD, US, NPV, Patient, Investment, Webcast, Depreciation, Growth, Neoplasm, Clothing, Medical imaging, Pharmaceutical industry, Cryptocurrency, Palladium

GUANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2023.

Key Points: 
  • GUANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2023.
  • Results of the MEDAL (MEthylation Based Dynamic Analysis for Lung Cancer) study were published at the American Association for Cancer Research Annual Meeting 2023 (“AACR 2023”).
  • The results of the clinical performance of brPROPHET™ in patients with resectable gastric cancer and biliary tract cancer were also released at AACR 2023.
  • Burning Rock will host a conference call to discuss the first quarter 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on May 30, 2023.

Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer

Retrieved on: 
Wednesday, May 31, 2023
Research, Medical Devices, Surgery, Women, Genetics, Biotechnology, Consumer, Health, Science, Oncology, Blueprint, Survival rate, Neoplasm, Survival, Quality of life, Woman, Prognosis, Immunotherapy, Gene expression profiling, MD, Patient, Map, Oncology nursing, News, Empowerment, Breast cancer, Medical imaging, MammaPrint

The study found that women with H2 risk tumors are more likely to respond to chemotherapy and have aggressive, Basal-type tumors compared to women with H1 risk tumors.

Key Points: 
  • The study found that women with H2 risk tumors are more likely to respond to chemotherapy and have aggressive, Basal-type tumors compared to women with H1 risk tumors.
  • While other gene expression profiling tests may lump women into broad-strokes risk groupings, MammaPrint is the only test that further subcategorizes both low risk (Low and Ultra Low), and high risk (H1 and H2) [1,2].
  • “Hearing that you have a high-risk tumor is scary news for any woman with early-stage breast cancer.
  • Of 327 women with MammaPrint High Risk tumors, 61% had H1 tumors, and 39% had H2 tumors.

Global Proteomics Market Report 2023: Sector is Expected to Reach $100.17 Billion by 2030 at a CAGR of 16.55% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 30, 2023
Health, Biotechnology, SPR, Chromatography, Proteomics, Prognosis, MEA, Genomics, Mass spectrometry, Protein, Biomarker, Drug discovery, Biology, Growth, Electrophoresis, Pharmaceutical industry, Medical imaging

The global proteomics market is driven by the increasing demand for personalized medicine, advancements in proteomics technologies, and the growing focus on drug discovery and development.

Key Points: 
  • The global proteomics market is driven by the increasing demand for personalized medicine, advancements in proteomics technologies, and the growing focus on drug discovery and development.
  • The global proteomics market is segmented based on the product, technology, application and region.
  • The proteomics market is expected to grow significantly due to various drivers, such as the increasing demand for personalized medicine.
  • The high cost of proteomics technologies is a major restraint for the growth of the proteomics market.

Ascentage Pharma's Novel Drug Olverembatinib Recommended for a Breakthrough Therapy Designation in China for the Treatment of SDH-Deficient GIST, the Second BTD for the Drug

Retrieved on: 
Wednesday, May 31, 2023
TKI, GIST, E pluribus unum, Priority review, Science, Malignancy, Drug development, Gastrointestinal tract, CML, New Drug Application, American Society of Clinical Oncology, Succinate dehydrogenase, NDA, Cancer, Quality of life, SDH, Mutation, CHB, BTD, BCR-ABL, Prognosis, Research, John-Ross Rizzo, Multimedia, CBR, Bangladesh Technical Education Board, ASCO, KIT, Patient, PDGFRA, Douglas BTD Destroyer, Annual general meeting, National Medical Products Administration, CDE, EFS, Center for Drug Evaluation and Research, Notifiable disease, Gastrointestinal stromal tumor, Society, NMPA, Hepatitis, Pharmaceutical industry, Silviculture

To date, olverembatinib has been granted two Priority Review Designations that underscored the drug's promising therapeutic utility.

Key Points: 
  • To date, olverembatinib has been granted two Priority Review Designations that underscored the drug's promising therapeutic utility.
  • Drugs that have been granted BTDs are prioritized by the CDE in communications and exchange, and in receiving guidance to advance the drug development progress.
  • Furthermore, BTD-designated drugs will be eligible for Priority Review status and conditional approvals upon submission of a New Drug Application (NDA).
  • Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)–resistant succinate dehydrogenase (SDH)–deficient gastrointestinal stromal tumor (GIST).

KAIST and Checkmate Capital Complete Investment in Bredis Healthcare

Retrieved on: 
Thursday, May 25, 2023
Pacific Ocean, Commercialization, Partnership, KAIST, Pusan National University, Prognosis, Research, Biomarker, ELISA, Dementia, Tomato bredie, Blood, Diagnosis, Ecosystem, Pharmaceutical industry, Medical imaging, Checkmate

SEOUL, Korea and PASADENA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- KAIST Venture Investment Holdings (“KAIST” or “KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“Bredis”). Bredis is a leading neurodegenerative diagnostics company that has pioneered its patent-protected, digital ELISA technology that is 10,000 times more sensitive than existing blood test technology.

Key Points: 
  • Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea
    SEOUL, Korea and PASADENA, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- KAIST Venture Investment Holdings (“KAIST” or “KAIST Ventures”), the venture investment fund of Korea Advanced Institute of Science and Technology, and an affiliate of Checkmate Capital Group, LLC (“Checkmate”), a cross-Pacific strategic advisory group and investment office, are pleased to announce the completion of their investment into Bredis Healthcare (“Bredis”).
  • KAIST led the redeemable convertible preferred stock investment and Checkmate was the sole non-Korean investor.
  • As a startup team from KAIST, we believe Bredis will become a promising biomarker-based diagnostics enterprise that grows rapidly through the KAIST startup ecosystem,” commented Henry Chung, CEO of KAIST Ventures.
  • “We are delighted that Bredis is Checkmate’s first direct investment in Korea, sourced through our new international office based in Seoul, and our first collaborative investment with our trusted partner, KAIST,” stated Jay Ryu, Managing Director of Checkmate.

Brain Cancer Canada Grants Research Funds to Improve Survival Rates for Glioblastoma and Other Gliomas

Retrieved on: 
Thursday, May 25, 2023
Sunnybrook, Canada, Glioblastoma, Prognosis, Research, Brain, Brain tumor, Patient, Neuro, Partnership, Sunnybrook Health Sciences Centre, Medical imaging

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.

Key Points: 
  • TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.
  • The grant will support a ground-breaking study to improve the treatment of high-grade gliomas, the most aggressive form of brain cancer.
  • “We are hopeful that this research will make a significant difference in the treatment of high-grade gliomas,” Dr. Singnurkar said.
  • “This research has the potential to be a game-changer in the treatment of high-grade gliomas, such as glioblastoma,” she said.